EP1591446A1 — Thienopyrimidine compounds and use thereof
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2005-11-02 · 21y expired
What this patent protects
The present invention provides a compound represented by the formula: wherein R 1 is a C 1-4 alkyl; R 2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2') a hydroxy group, (…
USPTO Abstract
The present invention provides a compound represented by the formula: wherein R 1 is a C 1-4 alkyl; R 2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2') a hydroxy group, (3') a C 1-4 alkyl and (4') a C 1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1') a halogen, (2') a C 1-4 alkoxy-C 1-4 alkyl, (3') a mono-C 1-4 alkyl-carbamoyl-C 1-4 alkyl, (4') a C 1-4 alkoxy and (5') a mono-C 1-4 alkylcarbamoyl-C 1-4 alkoxy, or the like; R 3 is a C 1-4 alkyl; R 4 is a C 1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.